NYSE:ADCT ADC Therapeutics (ADCT) Stock Price, News & Analysis $2.70 -0.13 (-4.59%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$2.67▼$2.8850-Day Range$2.59▼$4.0152-Week Range$0.36▼$6.04Volume227,639 shsAverage Volume701,891 shsMarket Capitalization$223.50 millionP/E RatioN/ADividend YieldN/APrice Target$9.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get ADC Therapeutics alerts: Email Address ADC Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside233.3% Upside$9.00 Price TargetShort InterestHealthy4.01% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 2 Articles This WeekInsider TradingAcquiring Shares$1.12 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($1.69) to ($1.32) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.86 out of 5 starsMedical Sector574th out of 910 stocksPharmaceutical Preparations Industry264th out of 426 stocks 3.4 Analyst's Opinion Consensus RatingADC Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageADC Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about ADC Therapeutics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.01% of the float of ADC Therapeutics has been sold short.Short Interest Ratio / Days to CoverADC Therapeutics has a short interest ratio ("days to cover") of 4.2.Change versus previous monthShort interest in ADC Therapeutics has recently decreased by 1.00%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldADC Therapeutics does not currently pay a dividend.Dividend GrowthADC Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ADCT. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for ADC Therapeutics this week, compared to 2 articles on an average week.Search Interest6 people have searched for ADCT on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ADC Therapeutics insiders have bought 5,459.95% more of their company's stock than they have sold. Specifically, they have bought $1,124,000.00 in company stock and sold $20,216.00 in company stock.Percentage Held by InsidersOnly 4.05% of the stock of ADC Therapeutics is held by insiders.Percentage Held by Institutions41.10% of the stock of ADC Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ADC Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for ADC Therapeutics are expected to grow in the coming year, from ($1.69) to ($1.32) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ADC Therapeutics is -0.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ADC Therapeutics is -0.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about ADC Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressEx-CIA Advisor: “This is How Kamala will Rig the Election”A former CIA advisor with close ties to the White House… Has just released this shocking expose on Kamala’s plan to stop Trump. Every American needs to prepare now…Click here now and learn how to prepare. About ADC Therapeutics Stock (NYSE:ADCT)ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.Read More ADCT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ADCT Stock News HeadlinesSeptember 3, 2024 | globenewswire.comADC Therapeutics Makes Grants to New Employees Under Inducement PlanSeptember 3, 2024 | globenewswire.comADC Therapeutics to Present at Upcoming Investor ConferencesSeptember 7, 2024 | Golden Crest (Ad)Biden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.August 8, 2024 | markets.businessinsider.comRBC Capital Reaffirms Their Buy Rating on ADC Therapeutics (ADCT)August 7, 2024 | markets.businessinsider.comBuy Rating Upheld for ADC Therapeutics SA Amidst Strong Financials and Promising Oncology PipelineAugust 6, 2024 | finanznachrichten.deADC Therapeutics SA: ADC Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational UpdateAugust 6, 2024 | globenewswire.comADC Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational UpdateAugust 1, 2024 | globenewswire.comADC Therapeutics Makes Grants to New Employees Under Inducement PlanSeptember 7, 2024 | Golden Crest (Ad)Biden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.July 30, 2024 | globenewswire.comADC Therapeutics to Host Second Quarter 2024 Financial Results Conference Call on August 6, 2024July 11, 2024 | investorplace.com7 Growth Stocks to Buy for Under $5 for Massive GainsJuly 8, 2024 | globenewswire.comMyricx Bio Announces £90m ($114m) Series A Financing to Advance its Novel NMTi-ADC Therapeutics into Clinical DevelopmentJune 27, 2024 | globenewswire.comADC Therapeutics Set to Join Russell 2000® and Russell 3000® IndexesJune 13, 2024 | investorplace.comStocks to Buy: 3 Biotech Bargains Delivering Breakthroughs on a BudgetJune 3, 2024 | globenewswire.comADC Therapeutics Makes Grants to New Employees Under Inducement PlanMay 30, 2024 | globenewswire.comADC Therapeutics to Participate in the Jefferies Global Healthcare ConferenceMay 15, 2024 | globenewswire.comADC Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQMay 10, 2024 | finance.yahoo.comADC Therapeutics First Quarter 2024 Earnings: In Line With ExpectationsSee More Headlines Receive ADCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ADC Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/06/2024Today9/07/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNYSE:ADCT CUSIPN/A CIK1771910 Webwww.adctherapeutics.com Phone41-21-653-0200FaxN/AEmployees310Year FoundedN/APrice Target and Rating Average Stock Price Target$9.00 High Stock Price Target$11.00 Low Stock Price Target$8.00 Potential Upside/Downside+233.3%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-240,050,000.00 Net Margins-323.60% Pretax Margin-249.82% Return on EquityN/A Return on Assets-57.54% Debt Debt-to-Equity RatioN/A Current Ratio6.17 Quick Ratio5.90 Sales & Book Value Annual Sales$66.75 million Price / Sales3.35 Cash FlowN/A Price / Cash FlowN/A Book Value($1.36) per share Price / Book-1.99Miscellaneous Outstanding Shares82,777,000Free Float79,425,000Market Cap$223.50 million OptionableOptionable Beta1.58 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Ameet Mallik M.B.A. (Age 51)M.S., CEO & Director Comp: $1.84MMr. Jose I. Carmona M.B.A. (Age 52)Chief Financial Officer Comp: $884.86kDr. Mohamed Zaki M.D. (Age 59)Ph.D., Chief Medical Officer Comp: $2.41MMs. Lisa Michelle KalleboCorporate Controller & Chief Accounting OfficerDr. Michael Mulkerrin Ph.D. (Age 69)Chief Technical Operations Officer Dr. Patrick van Berkel Ph.D. (Age 56)Chief Scientific Officer Amanda HamiltonInvestor Relations OfficerMr. Peter J. Graham Esq. (Age 57)Chief Legal Officer Ms. Eugenia LitzVice President of Investor Relations & Corporate CommunicationsMs. Kimberly Pope (Age 57)Senior VP & Chief People Officer More ExecutivesKey CompetitorsNektar TherapeuticsNASDAQ:NKTRMersana TherapeuticsNASDAQ:MRSNCytomX TherapeuticsNASDAQ:CTMXC4 TherapeuticsNASDAQ:CCCCVerve TherapeuticsNASDAQ:VERVView All CompetitorsInsiders & InstitutionsAffinity Asset Advisors LLCBought 474,744 shares on 8/15/2024Ownership: 0.574%The Manufacturers Life Insurance Company Bought 26,938 shares on 8/15/2024Ownership: 0.033%Susquehanna Fundamental Investments LLCBought 10,355 shares on 8/15/2024Ownership: 0.013%XTX Topco LtdBought 32,034 shares on 8/12/2024Ownership: 0.069%Acadian Asset Management LLCBought 16,454 shares on 8/6/2024Ownership: 0.020%View All Insider TransactionsView All Institutional Transactions ADCT Stock Analysis - Frequently Asked Questions How have ADCT shares performed this year? ADC Therapeutics' stock was trading at $1.66 on January 1st, 2024. Since then, ADCT shares have increased by 62.7% and is now trading at $2.70. View the best growth stocks for 2024 here. How were ADC Therapeutics' earnings last quarter? ADC Therapeutics SA (NYSE:ADCT) issued its earnings results on Tuesday, August, 6th. The company reported ($0.38) EPS for the quarter, beating analysts' consensus estimates of ($0.44) by $0.06. The business had revenue of $17.41 million for the quarter, compared to analysts' expectations of $19.06 million. When did ADC Therapeutics IPO? ADC Therapeutics (ADCT) raised $126 million in an initial public offering (IPO) on Friday, May 15th 2020. The company issued 7,400,000 shares at $16.00-$18.00 per share. Morgan Stanley, BofA Securities and Cowen and Company served as the underwriters for the IPO. Who are ADC Therapeutics' major shareholders? ADC Therapeutics' top institutional investors include Affinity Asset Advisors LLC (0.57%), Bank of New York Mellon Corp (0.25%), Sanibel Captiva Trust Company Inc. (0.14%) and Rhumbline Advisers (0.10%). Insiders that own company stock include Redmile Group, Llc, Ameet Mallik and Robert Azelby. View institutional ownership trends. How do I buy shares of ADC Therapeutics? Shares of ADCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of ADC Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that ADC Therapeutics investors own include CVS Health (CVS), RTX (RTX), Home Depot (HD), Procter & Gamble (PG), Thermo Fisher Scientific (TMO) and Alibaba Group (BABA). This page (NYSE:ADCT) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ADC Therapeutics SA Please log in to your account or sign up in order to add this asset to your watchlist. Share ADC Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
